Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
177Lu-Dotataat plus octreotide bij neuro-endocriene tumoren: NETTER-2
sep 2024 | Maag-darm-leveroncologie